Bio-IT World November 29, 2022
Funding for first-in-class peptide-drug conjugate for tumor cells, gene delivery research and development, next-generation orthopedic products, and more.
$120M: Series E Funding for Clinical-Stage Urologic Oncology Pipeline
CG Oncology announced the closing of an oversubscribed $120 million Series E financing round. The proceeds from the funding will be used to advance the company’s lead clinical programs in bladder cancer towards U.S. Food and Drug Administration approval and broaden the scope of its pipeline to address unmet medical needs in urologic cancer, such as the first line setting in Bacillus Calmette-Guérin (BCG)-naïve, intermediate-risk non-muscle invasive bladder cancer (NMIBC) patients. In addition, CG Oncology collaborates with Merck to evaluate the combination of its intravesically delivered oncolytic immunotherapy...
Today's Sponsors
Today's Sponsor